Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (10 ops.)
Latest filing published 16 Aug 2022 for Epizyme, Inc..
Filing timeline
BuySaleJoseph Beaulieu
Insider track record
Disclosed buys
0
Disclosed sells
10
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Joseph Beaulieu: trading record in brief
Joseph Beaulieu discloses dealings in Epizyme, Inc. to SEC (Form 4). We count 23 filings; the first trade dates from 12 June 2019 and the latest from 12 August 2022.
No open-market purchase appears, only 10 sales worth €57k. Outside the open market, there are 10 share grants and 1 option exercise. In 2022 alone, the filings show no purchases and 2 sales.
The record was last updated on 16 August 2022 with a transaction in Epizyme, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Joseph Beaulieu
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
30,181 sharesCommon Stock, par value $0.0001SEC:0000899243-22-028859:0
300,000 shares@ US$1.3998.8% of flowCommon Stock, par value $0.0001SEC:0000899243-22-028418:0
2,331 shares@ US$1.26650.6% of flowCommon StockSEC:0000899243-22-011728:0
222 shares@ US$1.500.1% of flowCommon Stock, par value $0.0001SEC:0000899243-22-005473:0
687 shares@ US$1.370.2% of flowCommon Stock, par value $0.0001SEC:0000899243-22-004826:0
14,833 shares0Common Stock, par value $0.0001SEC:0000899243-21-033404:0
6 of 6 declarations
